Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?

Ítems similars

• PCSK9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing
  per: Hess, Gregory P., et al.
  Publicat: (2017)
• The Patient Journey with PCSK9 Inhibitors in Community Practice
  per: Bradley, Corey K., et al.
  Publicat: (2019)
• Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy
  per: Navar, Ann Marie, et al.
  Publicat: (2017)
• Implications of the FDA approval of PCSK9 Inhibitors and FOURIER Results for Contemporary Cardiovascular Practice: An NCDR(®) Research to Practice (R2P) Project
  per: Hess, Paul L., et al.
  Publicat: (2017)
• Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives
  per: Arrieta, Alejandro, et al.
  Publicat: (2017)